EASL Clinical Practice Guidelines. Management of chronic hepatitis B;Recommandations de pratiques cliniques de l'EASL. Prise en charge de l'hépatite chronique B

Gastroenterologie Clinique et Biologique

Volumn 33, Issue 6-7, 2009, Pages 539-554

  European Association for the Study of the Liver, ^a  

^a EASL Office   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; TELBIVUDINE; TENOFOVIR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; CHRONIC HEPATITIS; DECOMPENSATED LIVER CIRRHOSIS; DELTA AGENT HEPATITIS; EUROPE; HEPATITIS B; HEPATITIS C; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MIXED INFECTION; PRACTICE GUIDELINE; SEROCONVERSION; SHORT SURVEY; TREATMENT RESPONSE; VIRUS MUTATION;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEALTH PERSONNEL; HEPATITIS B ANTIGENS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION;

EID: 67649467313     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2009.03.002     Document Type: Article

References (109)

1. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003;38:533-40.
2. Ganem D., and Prince A.M. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 350 (2004) 1118-1129
3. Hoofnagle J.H., Doo E., Liang T.J., Fleischer R., and Lok A.S. Management of hepatitis B: summary of a clinical research workshop. Hepatology 45 (2007) 1056-1075
4. Liaw Y.F. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma. Semin Liver Dis 25 (2005) 40-47
5. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539
6. Rizzetto M. Viral hepatitis in the third millennium. Res Virol 149 (1998) 251-256
7. Rizzetto M., and Ciancio A. Chronic HBV-related liver disease. Mol Aspects Med 29 (2008) 72-84
8. Zarski J.P., Marcellin P., Leroy V., Trepo C., Samuel D., Ganne-Carrie N., et al. Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J Hepatol 45 (2006) 355-360
9. Chu C.M., and Liaw Y.F. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 26 (2006) 142-152
10. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 23 (2003) 47-58
11. Fattovich G., Bortolotti F., and Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 48 (2008) 335-352
12. Fattovich G., Olivari N., Pasino M., D'Onofrio M., Martone E., and Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 57 (2008) 84-90
13. Fattovich G., Stroffolini T., Zagni I., and Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127 (2004) S35-S50
14. Martinot-Peignoux M., Boyer N., Colombat M., Akremi R., Pham B.N., Ollivier S., et al. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 36 (2002) 543-546
15. Hadziyannis S.J., and Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 34 (2001) 617-624
16. Raimondo G., Allain J.P., Brunetto M.R., Buendia M.A., Chen D.S., Colombo M., et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 49 (2008) 652-657
17. Knoll A., Pietrzyk M., Loss M., Goetz W.A., and Jilg W. Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV core antigen: low risk of HBV reactivation. Transplantation 79 (2005) 1631-1633
18. Marcellin P., Giostra E., Martinot-Peignoux M., Loriot M.A., Jaegle M.L., Wolf P., et al. Redevelopment of hepatitis-B surface antigen after renal transplantation. Gastroenterology 100 (1991) 1432-1434
19. Guyatt G.H., Cook D.J., Jaeschke R., Pauker S.G., and Schunemann H.J. Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (2008) 123S-131S
20. Guyatt G.H., Oxman A.D., Kunz R., Falck-Ytter Y., Vist G.E., Liberati A., et al. Going from evidence to recommendations. Br Med J 336 (2008) 1049-1051
21. Guyatt G.H., Oxman A.D., Kunz R., Jaeschke R., Helfand M., Liberati A., et al. Incorporating considerations of resources use into grading recommendations. Br Med J 336 (2008) 1170-1173
22. Guyatt G.H., Oxman A.D., Kunz R., Vist G.E., Falck-Ytter Y., and Schunemann H.J. What is "quality of evidence" and why is it important to clinicians?. Br Med J 336 (2008) 995-998
23. Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br Med J 336 (2008) 924-926
24. Jaeschke R., Guyatt G.H., Dellinger P., Schunemann H., Levy M.M., Kunz R., et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. Br Med J 337 (2008) 744
25. Schunemann H.J., Oxman A.D., Brozek J., Glasziou P., Jaeschke R., Vist G.E., et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. Br Med J 336 (2008) 1106-1110
26. Chevaliez S., Bouvier-Alias M., Laperche S., and Pawlotsky J.M. Performance of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. J Clin Microbiol 46 (2008) 1716-1723
27. Thibault V., Pichoud C., Mullen C., Rhoads J., Smith J.B., Bitbol A., et al. Characterization of a new sensitive PCR assay for quantification of viral DNA isolated from patients with hepatitis B virus infections. J Clin Microbiol 45 (2007) 3948-3953
28. Stelzl E., Muller Z., Marth E., and Kessler H.H. Rapid quantification of hepatitis B virus DNA by automated sample preparation and real-time PCR. J Clin Microbiol 42 (2004) 2445-2449
29. Pawlotsky J.M., Dusheiko G., Hatzakis A., Lau D., Lau G., Liang T.J., et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 134 (2008) 405-415
30. Saldanha J., Gerlich W., Lelie N., Dawson P., Heermann K., and Heath A. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 80 (2001) 63-71
31. Bedossa P., Dargere D., and Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38 (2003) 1449-1457
32. Poynard T., Morra R., Halfon P., Castera L., Ratziu V., Imbert-Bismut F., et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 7 (2007) 40
33. Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, de Lédinghen V, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int; in press.
34. Myers R.P., Tainturier M.H., Ratziu V., Piton A., Thibault V., Imbert-Bismut F., et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 39 (2003) 222-230
35. Ogawa E., Furusyo N., Toyoda K., Takeoka H., Otaguro S., Hamada M., et al. Transient elastography for patients with chronic hepatitis B and C virus infection: non-invasive, quantitative assessment of liver fibrosis. Hepatol Res 37 (2007) 1002-1010
36. Ngo Y., Benhamou Y., Thibault V., Ingiliz P., Munteanu M., Lebray P., et al. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. PLoS ONE 3 (2008) e2573
37. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
38. Chang T.T., Gish R.G., de M.R., Gadano A., Sollano J., Chao Y.C., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 (2006) 1001-1010
39. Janssen H.L., van Z.M., Senturk H., Zeuzem S., Akarca U.S., Cakaloglu Y., et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365 (2005) 123-129
40. Lai C.L., Chien R.N., Leung N.W., Chang T.T., Guan R., Tai D.I., et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339 (1998) 61-68
41. Lai C.L., Gane E., Liaw Y.F., Hsu C.W., Thongsawat S., Wang Y., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357 (2007) 2576-2588
42. Lau G.K., Piratvisuth T., Luo K.X., Marcellin P., Thongsawat S., Cooksley G., et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 (2005) 2682-2695
43. Marcellin P., Chang T.T., Lim S.G., Tong M.J., Sievert W., Shiffman M.L., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
44. Heathcote E.J., Gane E., Deman R., Lee S., Flisiak R., Manns M.P., et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAG positive chronic hepatitis B (CHB): Study GS-US-174-0103. Hepatology 46 (2007) 861A
45. Marcellin P., Lau G.K., Bonino F., Farci P., Hadziyannis S., Jin R., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351 (2004) 1206-1217
46. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 (2006) 1743-1751
47. Marcellin P., Buti M., Krastev Z., Germanidis G., Kaita K.D., Kotzev I., et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAG-negative chronic hepatitis B (CHB): Study GS-US-174-0102. Hepatology 46 (2007) 290A-291A
48. Lai C.L., Shouval D., Lok A.S., Chang T.T., Cheinquer H., Goodman Z., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354 (2006) 1011-1020
49. Tassopoulos N.C., Volpes R., Pastore G., Heathcote J., Buti M., Goldin R.D., et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 29 (1999) 889-896
50. Perrillo R.P., Schiff E.R., Davis G.L., Bodenheimer H.C., Lindsay K., Payne J., et al. A Randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 323 (1990) 295-301
51. Wong D.K., Cheung A.M., O'Rourke K., Naylor C.D., Detsky A.S., and Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B.A meta-analysis. Ann Intern Med 119 (1993) 312-323
52. Zoulim F., and Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 48 Suppl. 1 (2008) S2-S19
53. Bonino F., Marcellin P., Lau G.K., Hadziyannis S., Jin R., Piratvisuth T., et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 56 (2007) 699-705
54. Fried M.W., Piratvisuth T., Lau G.K.K., Marcellin P., Chow W.C., Cooksley G., et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 47 (2008) 428-434
55. Perrillo R.P., Lai C.L., Liaw Y.F., Dienstag J.L., Schiff E.R., Schalm S.W., et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 36 (2002) 186-194
56. Flink H.J., van Z.M., Hansen B.E., de Man R.A., Schalm S.W., and Janssen H.L. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 101 (2006) 297-303
57. Yuen M.F., Fong D.Y., Wong D.K., Yuen J.C., Fung J., and Lai C.L. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 46 (2007) 1695-1703
58. Heathcote J., George J., Gordon S., Bronowicki J.P., Sperl J., Williams R., et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 103). J Hepatol 48 Suppl. 2 (2008) S32
59. Marcellin P., Jacobson I., Habersetzer F., Senturk H., Andreone P., Moyes C., et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic heatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 102). J Hepatol 48 Suppl. 2 (2008) S26
60. Hadziyannis S.J., Papatheodoridis G.V., Dimou E., Laras A., and Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32 (2000) 847-851
61. Lok A.S., Hussain M., Cursano C., Margotti M., Gramenzi A., Grazi G.L., et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 32 (2000) 1145-1153
62. Lok A.S., Zoulim F., Locarnini S., Bartholomeusz A., Ghany M.G., Pawlotsky J.M., et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46 (2007) 254-265
63. Lampertico P., Vigano M., Manenti E., Iavarone M., and Colombo M. Add-on adefovir prevents the emergence of adefovir resistance in lamivudine-resistant patients: A 4-year study. J Hepatol 48 (2008) S259
64. Fournier C., and Zoulim F. Antiviral therapy of chronic hepatitis B: prevention of drug resistance. Clin Liver Dis 11 (2007) 869-892
65. Buster E.H., Hansen B.E., Buti M., Delwaide J., Niederau C., Michielsen P.P., et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology 46 (2007) 388-394
66. Perrillo R., Hann H.W., Mutimer D., Willems B., Leung N., Lee W.M., et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 126 (2004) 81-90
67. Fontana R.J., Hann H.W., Perrillo R.P., Vierling J.M., Wright T., Rakela J., et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 123 (2002) 719-727
68. Grellier L., Mutimer D., Ahmed M., Brown D., Burroughs A.K., Rolles K., et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348 (1996) 1212-1215
69. Samuel D. Management of hepatitis B in liver transplantation patients. Semin Liver Dis 24 Suppl. 1 (2004) 55-62
70. Schiff E., Lai C.L., Hadziyannis S., Neuhaus P., Terrault N., Colombo M., et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transplant 13 (2007) 349-360
71. Di M.V., Thevenot T., Colin J.F., Boyer N., Martinot M., Degos F., et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 123 (2002) 1812-1822
72. Hoffmann C.J., and Thio C.L. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 7 (2007) 402-409
73. Puoti M., Torti C., Bruno R., Filice G., and Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 44 (2006) S65-S70
74. Rockstroh J.K. Influence of viral hepatitis on HIV infection. J Hepatol 44 (2006) S25-S27
75. Soriano V., Puoti M., Bonacini M., Brook G., Cargnel A., Rockstroh J., et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 19 (2005) 221-240
76. Sulkowski M.S. Viral hepatitis and HIV coinfection. J Hepatol 48 (2008) 353-367
77. Alberti A., Clumeck N., Collins S., Gerlich W., Lundgren J., Palu G., et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 42 (2005) 615-624
78. Rockstroh J.K., Bhagani S., Benhamou Y., Bruno R., Mauss S., Peters L., et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 9 (2008) 82-88
79. Benhamou Y., Fleury H., Trimoulet P., Pellegrin I., Urbinelli R., Katlama C., et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 43 (2006) 548-555
80. Castelnau C., Le Gal F., Ripault M.P., Gordien E., Martinot-Peignoux M., Boyer N., et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 44 (2006) 728-735
81. Farci P. Treatment of chronic hepatitis D: new advances, old challenges. Hepatology 44 (2006) 536-539
82. Farci P., Chessa L., Balestrieri C., Serra G., and Lai M.E. Treatment of chronic hepatitis D. J Viral Hepat 14 (2007) 58-63
83. Farci P., Mandas A., Coiana A., Lai M.E., Desmet V., Van E.P., et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 330 (1994) 88-94
84. Niro G.A., Ciancio A., Gaeta G.B., Smedile A., Marrone A., Olivero A., et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 44 (2006) 713-720
85. Wedemeyer H., Yurdaydin C., Dalekos G., Erhardt A., Cakaloglu Y., Degertekin H., et al. 72 week data of the HIDIT-1 trial: a multicenter randomised study comparing peginterferon alpha-2a plus adefovir vs peginterferon alpha-2a plus placebo vs adefovir in chronic delta hepatitis. J Hepatol 46 Suppl. 1 (2007) S4
86. Yurdaydin C., Bozkaya H., Karaaslan H., Onder F.O., Erkan O.E., Yalcin K., et al. A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis. J Viral Hepat 14 (2007) 812-816
87. Potthoff A., Wedemeyer H., Boecher W.O., Berg T., Zeuzem S., Arnold J., et al. The HEP-NET B/C co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol 48 (2008) S320-S1320
88. Chu C.J., and Lee S.D. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 23 (2008) 512-520
89. Liu C.J., Chen P.J., Lai M.Y., Kao J.H., Jeng Y.M., and Chen D.S. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 37 (2003) 568-576
90. Senturk H., Tahan V., Canbakan B., Uraz S., Ulger Y., Ozaras R., et al. Chronic hepatitis C responds poorly to combination therapy in chronic hepatitis B carriers. Neth J Med 66 (2008) 191-195
91. Zhou J., Dore G.J., Zhang F., Lim P.L., and Chen Y.M.A. Hepatitis B and C virus coinfection in the TREAT Asia HIV observational database. J Gastroenterol Hepatol 22 (2007) 1510-1518
92. Lee W.M., Squires R.H., Nyberg S.L., Doo E., and Hoofnagle J.H. Acute liver failure: summary of a workshop. Hepatology 47 (2008) 1401-1415
93. Roussos A., Koilakou S., Kalafatas C., Kalantzis C., Apostolou N., Grivas E., et al. Lamivudine treatment for acute severe hepatitis B: report of a case and review of the literature. Acta Gastroenterol Belg 71 (2008) 30-32
94. Tillmann H.L., Hadem J., Leifeld L., Zachou K., Canbay A., Eisenbach C., et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 13 (2006) 256-263
95. Jonas M.M., Kelly D., Pollack H., Mizerski J., Sorbel J., Frederick D., et al. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to < 18 years) with chronic hepatitis B. Hepatology 47 (2008) 1863-1871
96. Jonas M.M., Little N.R., and Gardner S.D. Long-term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety. J Viral Hepat 15 (2008) 20-27
97. Pawlowska M., and Halota W. Virological response during treatment of chronic hepatitis B with pegylated interferon alfa-2a in children. Gastroenterology 134 (2008) A811
98. Sokal E.M., Kelly D., Wirth S., Mizerski J., Dhawan A., and Frederick D. The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection. J Clin Pharmacol 48 (2008) 512-517
99. Gunson R.N., Shouval D., Roggendorf M., Zaaijer H., Nicholas H., Holzmann H., et al. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol 27 (2003) 213-230
100. Terrault N.A., and Jacobson I.M. Treating chronic hepatitis B infection in patients who are pregnant or are undergoing immunosuppressive chemotherapy. Semin Liver Dis 27 Suppl. 1 (2007) 18-24
101. van Zonneveld M., van Nunen A.B., Niesters H.G., de Man R.A., Schalm S.W., and Janssen H.L. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 10 (2003) 294-297
102. ter Borg M.J., Leemans W.F., de Man R.A., and Janssen H.L. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat 15 (2008) 37-41
103. Hui C.K., Cheung W.W.W., Zhang H.Y., Au W.Y., Yueng Y.H., Leung A.Y.H., et al. Rituximab increases the risk of de novo hepatitis B infection in hepatitis B surface antigen negative patients undergoing cytotoxic chemotherapy. J Gastroenterol Hepatol 21 (2006) A73-A74
104. Lalazar G., Rund D., and Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Hematol 136 (2007) 699-712
105. Mindikoglu A.L., Regev A., and Schiff E.R. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 4 (2006) 1076-1081
106. Hsu C., Hsiung C.A., Su L.J., Hwang W.S., Wang M.C., Lin S.F., et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 47 (2008) 844-853
107. Hui C.K., Liang R., and Lau G.K. Kinetics of hepatitis B virus reactivation after chemotherapy: More questions than answers. Gastroenterology 131 (2006) 1656-1657
108. Lau G.K.K. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2 (2008) 152-162
109. Rostaing L., Henry S., Cisterne J.M., Duffaut M., Icart J., and Durand D. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 64 (1997) 1624-1627